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Abstract: Alterations in connective tissue collagen are prominent
features of both chronologically aged and photoaged (ageing
because of sun exposure) human skin. These age-related
abnormalities are mediated in part by cysteine-rich protein 61
(CCN1). CCN1 is elevated in the dermis of both chronologically
aged and photoaged human skin in vivo and promotes aberrant
collagen homeostasis by down-regulating type I collagen, the
major structural protein in skin, and promoting collagen
degradation. Vitamin A and its metabolites have been shown to
improve chronologically aged and photoaged skin by promoting
deposition of new collagen and preventing its degradation. Here,
we investigated regulation of CCN1 expression by retinoids in
skin equivalent cultures and chronologically aged and photoaged
human skin in vivo. In skin equivalent cultures, all-trans retinoic
acid (RA), the major bioactive form of vitamin A in skin,
significantly increased type I procollagen and reduced collagenase
(matrix metalloproteinases-1, MMP-1). Addition of recombinant
human CCN1 to skin equivalent cultures significantly reduced
type I procollagen and increased MMP-1. Importantly, RA
significantly reduced CCN1 expression in skin equivalent cultures.
Topical treatment with retinol (vitamin A, 0.4%) for 7 days
significantly reduced CCN1 mRNA and protein expression in both
chronologically aged (80 + years) and photoaged human skin in
vivo, compared to vehicle-treated skin. These data indicate that
the mechanism by which retinoids improve aged skin, through
increased collagen production, involves down-regulation of CCN1.
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Introduction
Type I collagen comprises the bulk of dermal connective tissue,
which physically supports human skin (1–3). Alterations in dermal
collagen organization, structure, and content occur in both chro-
nologically aged and photoaged human skin (1–4). These abnor-
malities are largely caused by an imbalance of collagen
homeostasis, characterized by reduced production of type I colla-
gen and elevated matrix-degrading matrix metalloproteinases
(MMPs)1 (5–8). This imbalance of collagen homeostasis is associ-
ated with the wrinkled appearance of photoaged skin and the
thinning of aged skin.
Human skin has the capacity to convert vitamin A (all-trans
retinol) to its biologically active metabolite all-trans retinoic acid
(RA). Treatment of aged or photoaged skin with retinol or RA
stimulates collagen production in both chronologically aged and
photoaged human skin (5,9,10). This stimulation improves the
appearance and function of skin. The molecular mechanisms by
which RA regulates collagen production in aged and photoaged
skin are not well understood. Recently, the CCN (cysteine-rich
protein 61, connective tissue growth factor, nephroblastoma over-
expressed) family member (11–13), cystein-rich protein 61
(CCN1) has been shown to inhibit type I procollagen synthesis
and induce collagen degradation via up-regulation of collagenase
matrix metalloproteinases-1 (MMP-1) (14,15). CCN1 has been
shown to exhibit diverse cellular functions such as regulation of
cell proliferation, chemotaxis, inflammation, apoptosis, adhesion,
motility and extracellular matrix remodeling (11,13,16–18). CCN1
expression is highly induced by various stimuli such as phorbol
ester TPA, Vitamin D, inflammation and wound healing
(16,18,19). On the other hand, CCN1 expression is inhibited by
retinoic acid in breast cancer cell lines (19). We have previously
reported that CCN1 is predominantly expressed by dermal fibro-
blasts and is significantly elevated in photoaged and chronologi-
cally aged human skin in vivo (14). As elevated CCN1 negatively
regulates collagen homeostasis and RA improves aberrant collagen
homeostasis, we investigated whether RA is able to regulate CCN1
expression in skin equivalent cultures and in human skin in vivo.
Our data indicate that treatment of skin equivalent cultures or
aged ⁄ photoaged human skin in vivo with RA significantly reduced
CCN1 and that this reduction was associated with increased type I
procollagen production and reduced MMP-1 expression. These
data suggest that the mechanism by which retinoids improve col-
lagen homeostasis in aged human skin involves suppression of
CCN1 expression.
Abbreviations: AFM, atomic force microscopy; CCN, cysteine-rich
protein 61, connective tissue growth factor, nephroblastoma overexpressed;
CCN1, cysteine-rich protein 61; CRABP-2, cellular RA-binding protein II;
ECM, extracellular matrix; MMP-1, matrix metalloproteinase-1; 1MMPs,
matrix metalloproteinases; PCR, polymerase chain reaction; RA, all-trans-
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Materials and methods
Procurement of human tissue samples and retinol treatment
in human skin in vivo
Full-thickness punch biopsies (4 mm) were obtained from healthy
adult human volunteers, as previously described (4,20). For young
and chronologically aged skin, the biopsies were obtained from
healthy sun-protected buttock skin according to age: 21–30 years
for young group and ‡80 years for aged group. For photoaged
skin, the biopsies were obtained from the extensor forearm and
sun-protected skin was biopsied from underarm of same individ-
ual. The age of photoaged subjects involved in this study ranged
from 55 to 65 years. The presence of severe photodamage was
determined based on clinical criteria, as described previously (5).
For retinol treatment, retinol (vitamin A, 0.4%) and its vehicle
(70% ethanol, 30% polyethylene glycol, and 0.05% butylated hy-
droxytoluene) were applied topically to sun-protected buttock skin
(chronologically aged group) and photoaged forearm skin for
7 days at single treatment. The retinol and its vehicle were applied
under occlusion to prevent loss and exposure to light. All proce-
dures involving human volunteers were approved by the Univer-
sity of Michigan Institutional Review Board, and all volunteers
provided written informed consent.
Atomic force microscopy (AFM) imaging
Human skin equivalent culture and human skin biopsies were
embedded in OCT, and cryo-sections (10 lm) were attached onto
the microscope cover glass (1.2 mm diameter; Fisher Scientific
Co., Pittsburgh, PA, USA). These AFM samples were allowed to
air dry for at least 24 h before imaging them to AFM analysis.
AFM images were carried out using a Multimode Nanoscope IIIa
AFM (Veeco Instrument Inc., Santa Barbara, CA, USA) equipped
with a 120 · 120 · 3.2 lm (X,Y,Z dimension) tube J scanner. An
initial scan position of the skin was determined by light optical
image. AFM images were obtained with tapping mode using a sili-
con etched cantilever (NSC15 ⁄ AIBS; MikroMasch, San Jose, CA,
USA) with a full tip cone angle 40º and the tip radius of curva-
ture 10 nm. AFM images were acquired at a scan rate of 1.0 Hz,
512 · 512 pixels resolution, integral and proportional gain settings
of 0.4 and 0.6, respectively. The image quality was optimized by
dynamically lowering the scan rate and setpoint and increasing the
gains and drive amplitude.
Immunohistology
Immunohistology was performed as described previously (14,21).
Briefly, skin OCT-embedded cryo-sections (7 lm) were fixed in
paraformaldehyde. Subsequently, the slides were incubated for 1 h
at room temperature with normal rabbit serum followed by incu-
bation of goat polyclonal antibodies against CCN1 (sc-8560; Santa
Cruz Biotechnology, Santa Cruz, CA, USA). To verify antibody
specificity, antibodies were incubated with antigenic peptides
(Santa Cruz Biotechnology) for 30 min prior to addition to skin
sections. All sections were lightly counterstained with haematoxy-
lin and were mounted with mounting media (Vector Laboratories,
Burlingame, CA, USA). The intensity of positive staining was
quantified by computerized image analysis (Image-pro Plus soft-
ware, version 4.1; Media Cybernetics, MD, USA).
Quantitative real-time RT-PCR
Total RNA was extracted from skin equivalent cultures and human
skin using Micro RNA isolation kit (Stratagene, La Jolla, CA, USA).
Total RNA (100 ng) was reverse transcribed, with random primers,
using Taqman Reverse Transcription kit (Applied Biosystems, Fos-
ter City, CA, USA). Real-time PCR was performed on a 7300
Sequence Detector (Applied Biosystems) using Taqman Universal
PCR Master Mix Reagents (Applied Biosystems). Primers and
probes for real-time PCR are as follows: CCN1, sense primer, 5¢-
TCAAAGACCTGTGGAACTGGTATC-3¢; anti-sense primer, 5¢-CA
CAAATCCGGGTTTCTTTCA-3¢; probe, 5¢-CAATGACAACCCTGA
GTGCCGCCT-3¢; CRABP-2, sense primer, 5¢-CAAGACCTCGT
GGACCAGAGA-3¢; anti-sense primer, 5¢-ACCCTGGTGCACACA
ACGT-3¢; probe, 5¢-TCCGCCGTCATGGTCAGGATCAGTTC-3¢.
Primers and probes for 36B4, type I procollagen and MMP-1 were
described previously (1,21–23). Target genes and 36B4 mRNA levels
were quantified and normalized to 36B4, a housekeeping control.
Skin equivalent cultures
Human skin equivalent cultures (EpiDermTM-FT-400) were kindly
provided by MatTek Corporation (Ashland, MA, USA). Skin
equivalent cultures consist of type I collagen and two major cell
types of human skin, keratinocytes and fibroblasts derived from
same donors. Upon receipt, the tissues were cultured in 2.0-ml
EFT-400 medium and equilibrated at 37C, 5% CO2 for 24 h. At
the end of equilibration, the tissues were treated with all-trans-ret-
inoic acid (10 lm; Sigma, Saint Louis, MO, USA) for 7 days (fresh
retinoic acid-containing medium was replaced every other day) or
recombinant human CCN1 (10 lg ⁄ ml; PeproTech, Rocky Hill,
NJ, USA) for 24 h. Throughout the experiment, the skin equiva-
lent cultures were cultured at air-liquid interface with the lower
dermis submerged in culture media and the epidermis exposed to
air. At the end of the treatment, both media and cells were col-
lected for analysis.
Western blot analysis and enzyme-linked immunosorbent
assay (ELISA)
Western blot was performed as described previously (14,24).
Briefly, whole cell extract was resolved on 10% SDS–PAGE, trans-
ferred to PVDF membrane and blocked with PBST (0.1% Tween
20 in PBS) containing 5% milk. Primary antibodies (CCN1; Santa
Cruz Biotechnology; Type I procollagen; Southern Biotechnology,
Birmingham, AL; MMP-1; Chemicon, CA, USA) were incubated
with PVDF membrane for 1 h at room temperature. Blots were
washed three times with PBST solution and incubated with appro-
priate secondary antibody for 1 h at room temperature. After
washing three times with PBST, the blots were developed with
ECF (Vistra ECF Western Blotting System; GE Healthcare, Piscata-
way, NJ, USA) and were scanned by STORM PhosphorImager
(Molecular Dynamics, Sunnyvale, CA, USA). The intensities of
specific bands were quantified and normalized using b-actin as a
marker for loading control. Secreted type I procollagen from skin
equivalent cultures was determined by procollagen type I C-pep-
tide in vitro enzyme-linked immunosorbent assay (Takara Bio
Inc., Madison, WI, USA) according to the manufacturer’s instruc-
tions and previous publication (25).
Statistical analysis
Comparisons between groups were determined with the Student’s
t-test. All P values are two-tailed and considered significant when
P < 0.05.
Results
RA responsiveness in skin equivalent cultures
Retinoids have been shown to regulate collagen homeostasis by
stimulation of type I collagen production and reducing collagen
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degradation in chronologically aged (9,10) and photoaged human
skin (5,20,26,27). The molecular mechanisms by which retinoids
regulate collagen homeostasis in human skin have been difficult to
investigate largely because of lack of appropriate in vitro models.
For example, primary keratinocytes or dermal fibroblasts are mini-
mally responsive to RA treatment in monolayer culture (28,29).
This lack of responsiveness is due, at least in part, to low levels of
nuclear retinoid receptors, which mediate expression of retinoid-
regulated genes (30,31). Therefore, we evaluated the use of skin
equivalent cultures as a model to investigate retinoid regulation of
collagen homeostasis. Skin equivalent cultures are composed of
stratified, differentiated keratinocytes (model epidermis) on top of
a type I collagen lattice, in which dermal fibroblasts are embedded
(model dermis).
We used AFM to characterize the structure and surface topol-
ogy of collagen fibrils in skin equivalent cultures and human der-
mis. AFM images show that the collagenous extracellular matrix
in skin equivalent cultures and human dermis are morphologically
similar (Fig. 1a). Collagen fibrils are formed into a sheet in both
skin equivalent cultures and human dermis. The measurement of
dermal surface roughness shows that no significant difference is
found between skin equivalent cultures and human dermis
(Fig. 1b).
Treatment of skin equivalent cultures with RA significantly
increased the number of keratinocyte layers (Fig. 1c). Thickness of
the keratinocyte layers was significantly increased (50%, Fig. 1d),
similar to the effect of topical application of RA to human skin
in vivo. (9,20,32). Consistent with these data, RA treatment signifi-
cantly increased (2.3-fold) CRABP-2 (cellular RA-binding protein
II) mRNA levels (Fig. 1e). The CRABP-2 gene is directly regulated
by nuclear retinoic acid receptors and is a well-characterized mar-
ker of nuclear retinoic acid receptor activation in human skin
(27,31,33–35). These histological and molecular changes in
response to RA treatment indicate that skin equivalent cultures
are a useful model for investigating mechanisms by which reti-
noids regulate collagen homeostasis in human skin.
RA increases type I procollagen and reduces MMP-1 in skin
equivalent cultures
Importantly, RA treatment significantly increased type I procolla-
gen mRNA (Fig. 2a) and protein levels (Fig. 2b) in skin equivalent
cultures, compared to vehicle control. Treatment with RA (10 lm)
for 24 h increased type I procollagen mRNA and protein levels
nearly 3-fold. In addition, RA treatment increased the level of
extracellular, secreted type I procollagen more than 2-fold
(Fig. 2c). RA treatment also significantly reduced the expression of
MMP-1, which initiates cleavage of type I collagen fibrils. RA
reduced MMP-1 mRNA (Fig. 2d) and protein (Fig. 2e) approxi-
mately 50%, in skin equivalent cultures, compared to vehicle con-
trol. These data indicate that RA regulates collagen homeostasis,
in skin equivalent cultures, as observed in human skin in vivo by
up-regulation of type I procollagen and down-regulation of
MMP-1.
RA reduces CCN1 expression, which negatively regulates
collagen homeostasis in skin equivalent cultures
We have previously reported that overexpression of CCN1 in
human skin fibroblast monolayer cultures alters collagen homeo-
stasis (14). To further investigate the functions of CCN1, skin
equivalent cultures were treated with recombinant human CCN1





















































































Figure 1. Organization of collagen fibrils and RA responsiveness in skin equivalent
cultures. (a) Skin equivalent cultures and human skin were embedded in OCT, and
cryo-sections (7 lm) were analysed by atomic force microscopy (AFM). AFM
images were obtained using a Multimode Nanoscope IIIa AFM (Veeco Instrument
Inc.,), as described in Experimental Procedures. Images are representative of three
experiments. Bar = 1 lm. Arrows indicate collagen bundles in skin equivalent
cultures and human skin (b) Skin dermal roughness was determined by Nanoscope
IIIa software. Data are expressed as mean ± SEM, N = 4. (c) Skin equivalent
cultures were treated with all-trans retinoic acid (10 lM) for 7 days. Cultures were
embedded in OCT, and cryo-sections (7 lm) were stained with H&E. Lines indicate
dermal–epidermal boundary. Images are representative of three experiments. (d)
Average vertical height of the stratified layers of keratinocytes was quantified by
computerized image analysis. Data are expressed as mean ± SEM, N = 3,
*P < 0.05. (e) CRABP-2 mRNA levels were quantified by real-time RT-PCR and
were normalized to mRNA for 36B4, a ribosomal protein used as an internal































































































































































Figure 2. all-trans retinoic acid increases type I procollagen and reduces matrix
metalloproteinases-1 (MMP-1) in skin equivalent cultures. Skin equivalent cultures
were treated with all-trans retinoic acid (10lM) for 7 days. (a) Type I procollagen
mRNA; (b) Type I procollagen protein (Western blot), (c) Type I procollagen protein
(ELISA); (d) MMP-1 mRNA; (e) MMP-1 protein (Western blot). mRNA levels were
quantified by real-time RT-PCR and were normalized to mRNA for 36B4, a
ribosomal protein used as an internal control for quantification. Western blot
analyses were normalized using b-actin as loading control. Inset shows
representative Western blots. Secreted type I procollagen (c) in culture medium
was determined by ELISA. Data are expressed as mean ± SEM, N = 3, *P < 0.05.
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rhCCN1 significantly reduced the levels of type I procollagen
mRNA (Fig. 3a) and protein (Fig. 3b) approximately 40%, com-
pared to vehicle control. In addition, CCN1 treatment of skin
equivalent cultures increased MMP-1 mRNA (Fig. 3c) and protein
(Fig. 3d) approximately 2.5-fold, compared to vehicle control in
skin equivalent cultures. These data indicate that collagen metabo-
lism by fibroblasts in skin equivalent cultures is regulated by
CCN1.
Given the ability of RA and CCN1 to regulate collagen homeo-
stasis in skin equivalent cultures, we next investigated whether RA
could alter CCN1 expression. Importantly, treatment of skin
equivalent cultures with RA (10 lm) for 7 days reduced the
expression of CCN1 mRNA (Fig. 3e) protein (Fig. 3f) by approxi-
mately 60%. Taken together, the above data indicate that RA reg-
ulates both collagen homeostasis and CCN1 expression in skin
equivalent cultures.
CCN1 is elevated in chronologically aged and photoaged
human skin and reduced by retinoid treatment in vivo
We have previously reported that CCN1 is elevated in ageing skin
determined by RT-PCR and Western blot analysis (14). To further
investigate the expression and localization of CCN1 in skin ageing,
we determined CCN1 expression and localization in naturally aged
and photoaged human skin by immunohistology. Immunohisto-
chemical staining of CCN1 protein was significantly elevated in
the dermis of both naturally aged (80 + years), sun-protected but-
tocks skin (Fig. 4a) and photoaged extensor forearm skin
(Fig. 4b), compared to young or subject-matched underarm (sun-
protected) skin, respectively. Levels of CCN1 protein were elevated
3- to 4-fold in the dermis of both naturally aged and photoaged
skin, compared to their respective controls. As elevated CCN1
negatively regulates collagen homeostasis, we investigated the
effect of retinoid treatment on CCN1 expression in human skin
in vivo. Retinol (0.4%) or vehicle was topically applied under
occlusion for 7 days to aged (80 + years) buttocks skin or photo-
aged extensor forearm skin. Application of retinol significantly
reduced elevated CCN1 in both naturally aged and photoaged
human skin, compared to vehicle-treated control skin. Retinol
reduced the dermal expression of CCN1 mRNA and protein by
50–70% in both naturally aged (Fig. 4c,d) and photoaged forearm
(Fig. 4e,f) skin in vivo, compared to vehicle-treated control skin.
Discussion
Chronologically aged and photoaged skin (photoageing) share
common molecular features such as altered homeostasis of type I
collagen, characterized by decreased collagen synthesis and ele-
vated collagen degradation. Alterations in connective tissue colla-
gen reduce the structural integrity and increase the fragility of
skin, thereby significantly impairing skin function. Alterations in
dermal collagen homeostasis are mediated, at least in part, by



























































































































































































Figure 3. CCN1 regulates collagen homeostasis, and retinoic acid reduces CCN1
expression in skin equivalent cultures. Skin equivalent cultures were treated with
recombinant human CCN1 (10 lg ⁄ ml) for 24 h. (a) Type I procollagen mRNA
levels; (b) type I procollagen protein levels; (c) Matrix metalloproteinases-1 (MMP-1)
mRNA levels; (d) MMP-1 protein levels. mRNA levels were quantified by real-time
RT-PCR and were normalized to mRNA for 36B4, a ribosomal protein used as an
internal control for quantification. Western blot analyses were normalized using b-
actin as loading control. Inset shows representative Western blots. (e,f) Cultures
were treated with all-trans retinoic acid (10 lM) for 7 days. (e) CCN1 mRNA levels;
(f) CCN1 protein levels. mRNA levels were quantified by real-time RT-PCR and were
normalized to mRNA for 36B4, a ribosomal protein used as an internal control for
quantification. Western blot analyses were normalized using b-actin as loading
control. Inset shows representative Western blots. Data are expressed as



























































































































































































Figure 4. Retinoid treatment reduces CCN1 expression in chronologically aged
and photoaged human skin in vivo. Full-thickness human skin punch biopsies were
obtained from (a) young (21–30 years) and aged (80 + years) buttock skin, or (b)
sun-protected underarm and subject-matched photoaged extensor forearm skin.
CCN1 protein levels were determined by immunohistology and quantified by
computerized image analysis. Figures show representative immunohistology. Data
are expressed as means ± SEM, n = 9, *P < 0.05. (c and d), Aged (80 + years)
buttocks skin was topically treated with vehicle or retinol (ROL, 0.4%) for 7 days.
(c) CCN1 mRNA levels, (d) CCN1 protein levels. (e and f), Photodamaged forearm
skin was topically treated with vehicle or retinol (ROL, 0.4%) for 7 days. (e) CCN1
mRNA levels, (f) CCN1 protein levels. CCN1 mRNA levels were quantified by real-
time RT-PCR and were normalized to mRNA for 36B4, a ribosomal protein used as
an internal control for quantification. CCN1 protein levels were determined
immunohistology and quantified by computerized image analysis. Inset shows
representative immunohistology. Data are expressed as means ± SEM, n = 4–10,
*P < 0.05.
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expressed in dermal fibroblasts and elevated in chronologically
aged, photoaged and UV-irradiated human skin dermis in vivo
(14,15). Elevated CCN1 negatively regulates collagen homeostasis
by inhibiting type I collagen production and promoting collagen
degradation.
Retinoids have been used as therapeutic agents for numerous
skin diseases, including psoriasis, acne, and photodamage (36).
However, the precise mechanism(s) by which RA improves clinical
features and skin function in chronologically aged or photoaged
skin is not well understood. Our data suggest that one mechanism
by which RA improves skin connective tissue may involve sup-
pression of CCN1 in aged human skin.
As retinoids have been shown to increase collagen production
in chronologically aged and photoaged skin (5,9,10,20), we inves-
tigated the effect of retinoids on CCN1 expression in human skin
in vivo, and in skin equivalent cultures in vitro. Our data indicate
that retinoid treatment significantly reduces CCN1 mRNA and
protein levels in aged or photoaged human skin in vivo, and in
skin equivalent cultures. This reduction is associated with
increased type I procollagen production and reduced MMP-1
expression in skin equivalent cultures.
The mechanism(s) by which retinoids reduce CCN1 expression
in chronologically aged or photoaged human skin remains to be
determined. One possibility is that retinoid reduces CCN1
through inhibition of AP-1 transcription factor. CCN1 has been
shown to be transcriptionally activated by a variety of extracellular
stimuli. We have found that transcriptional regulation of CCN1 in
response to UV irradiation is primarily controlled by AP-1 tran-
scription factor, in primary human dermal fibroblasts (15). AP-1
transcriptional activity is elevated in both chronologically aged
and photoaged human skin and is critically important in mediat-
ing skin connective tissue damage. Importantly, elevated AP-1 is
suppressed by applications of retinoid in aged and photoaged
human skin in vivo (5,10,27,37,38), suggesting that retinoids
down-regulate CCN1 expression by inhibiting AP-1 transcription
factor. Interestingly, we have reported that elevated CCN1 also
activates transcription factor AP-1, (14) suggesting that a positive
feedback mechanism may contribute to sustained elevation of
CCN1 in aged and photoaged human skin.
Treatment of skin equivalent cultures with RA resulted in
increased epidermal cell layers and CRABP-2 expression, which
are characteristic responses of human epidermis to retinoid treat-
ment in vivo. Skin equivalent cultures have been shown to be a
useful model to study functional interactions between epidermis
and dermis (39–41). We find that neither CCN1 nor type I colla-
gen is regulated by retinoid in primary fibroblasts cultured in
monolayer or three dimensional collagen lattices (data not
shown). An increasing body of evidence indicates that interactions
between epidermal keratinocytes and dermal fibroblasts play a piv-
otal role in dermal fibroblasts behaviour and functions (42–45).
Our data suggest that such interactions may be involved in the
regulation of CCN1 expression by retinoid, in dermal fibroblasts,
and skin equivalent cultures appear to be a useful model to inves-
tigate the nature of these interactions. In summary, our data sug-
gest that the mechanism by which retinoids improve collagen
homeostasis in aged and photoaged human skin involves suppres-
sion of CCN1 expression.
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